Topics:

Docetaxel in Combination With Platinums in Patients With Advanced Non- Small-Cell Lung Cancer

Docetaxel in Combination With Platinums in Patients With Advanced Non- Small-Cell Lung Cancer

ABSTRACT: Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non-small-cell lung cancer. In previously untreated patients with non-small-cell lung cancer, 100 mg/m²of docetaxel administered as an intravenous infusion over 1 hour once every 3 weeks produced response rates that ranged from 21% to 38% and median survivals of 25.2 to 47.0 weeks. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, docetaxel produced median response rates of 20% to 21% and median survival of 28 to 42 weeks. This review summarizes results from key phase I and II studies demonstrating the antitumor activity and tolerability of docetaxel combined with platinum compounds for patients with advanced non-small-cell lung cancer. Phase I trials determined that 75 mg/m² of docetaxel and 75 mg/m² of cisplatin is the recommended dose for phase II and III trials. Overall, response rates with docetaxel and cisplatin have ranged from 21% to 48% and median survival of 8 to 13 months has been achieved in phase II trials. Regarding docetaxel and carboplatin, results from phase I trials in patients with nonhematologic solid tumors indicate that this combination is well tolerated. The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL · min) is 90 mg/m² without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m² with G-CSF support. The combination of docetaxel and carboplatin is presently being evaluated in a multicenter phase II study for patients with advanced non-small-cell lung cancer. [ONCOLOGY 11(Suppl 8):42-45, 1997]

Introduction

Docetaxel (Taxotere), partially synthesized from 10-deacetylbaccatin III, is isolated from the needles of the European yew tree, Taxus baccata. It promotes tubulin assembly, thus disrupting the normal dynamic reorganization of the microtubule network, essential for vital interphase and mitotic function.[1,2]

Docetaxel has demonstrated activity in phase II trials, in patients with previously untreated non-small-cell lung cancer (NSCLC), and in those who have progressed after receiving cisplatin (Platinol)-based combinations (Table 1). The response rates range from 21% to 38% in chemotherapy-naive patients with advanced or recurrent non-small-cell lung cancer, and the median survival in these phase II studies varies from 25.2 to 47.0 weeks.[3-9] Docetaxel also has modest activity in patients who have either progressed after initial treatment with cisplatin-containing regimens, with response rates of 20% to 21% and median survival of 28 to 42 weeks.[5,10,11]

A recently reported large, multicenter study[12] confirmed the activity observed in previous studies in platinum-treated and/or refractory non-small-cell lung cancer with 1-year survival of 25%. Myelosuppression continues to be the main side effect associated with docetaxel in all the studies.[3-11] Other unique toxicities include nail changes, hypersensitivity reactions, and symptomatic peripheral edema and effusions.

Gandara et al[11] observed a 19% incidence of febrile neutropenia among 80 patients who were treated with docetaxel, and Cerny et al[3] reported a 67% incidence of grade 3 to 4 neutropenia. The fluid retention observed in the study from Memorial Sloan-Kettering Cancer Center reported by Miller and colleagues[8] appeared to be cumulative. Symptomatic pleural effusions developed in 6 of 8 patients who received a total dose of docetaxel greater than 500 mg/m². To further investigate the activity of docetaxel in the salvage setting after initial treatment or failure with cisplatin regimens, two large randomized studies are being conducted (Figure 1).

Development of Docetaxel/Cisplatin/Carboplatin Combination Regimens for Patients With NSCLC

Cisplatin has been used for the treatment of patients with non-small-cell lung cancer over the past two decades. Meta-analysis of randomized studies[12] comparing cisplatin-containing combination chemotherapy to best supportive care in advanced non-small-cell lung cancer demonstrated a modest but significant improvement in survival in favor of chemotherapeutic intervention. Thus, cisplatin appeared to be suitable for combination with docetaxel for further evaluation.

The phase I studies[13,14] of the combination of docetaxel and cisplatin established the doses of the two agents in the combination for further evaluation. The recommended dose of 75 mg/m² of docetaxel in combination with 75 mg/m² of cisplatin, with cycles repeated every 3 weeks, was used in our study.[15] In this multicenter trial, 47 previously untreated patients with advanced, metastatic non-small-cell lung cancer received a total of 229 courses of therapy. The salient toxicities were febrile neutropenia (8.5%), grade 4 pulmonary toxicity (4.3%), neuromotor effects (2.1%), and asthenia (12.8%). Symptomatic fluid retention occurred in only 1 patient, and other rare toxicities included nausea, vomiting, diarrhea, and stomatitis. Using stringent response criteria, the observed response rate was 21.3% (10.7% to 35.7%; 95% confidence interval), with 1 complete response and 9 partial responses, and the median survival of all patients is 10+ months.[15]

This combination has been evaluated in three additional studies conducted in Australia,[16] France,[17] and Greece.[18] The design and schema of these trials were slightly different, as shown in Table 2. With an increase in dose of either cisplatin to 100 mg/m² [17] or docetaxel to 100 mg/m²,[18] the degree and incidence of myelosuppression was higher. The median survival in all these trials ranges from 8 to 13 months. Based on the activity seen with the combination of docetaxel and cisplatin, this regimen is being evaluated further in the ongoing, randomized Eastern Cooperative Oncology Group (ECOG) study (Figure 2) for patients with advanced and metastatic non-small-cell lung cancer.

Carboplatin (Paraplatin), developed as the less toxic analog of cisplatin, has marginal but consistent activity in non-small-cell lung cancer.[19-21] In a large ECOG randomized study[19] comparing three cisplatin-based combination chemotherapy regimens to single agent therapy with carboplatin or iproplatin, the best survival was observed on the carboplatin arm. Thus, carboplatin also appeared to be a suitable agent for combination with docetaxel.

We performed a phase I study[22] of the combination of docetaxel and carboplatin to characterize the toxicity and establish the doses of the two agents. The results of this study were presented at the American Society of Clinical Oncology 1997 meeting.[22] The dose of docetaxel was escalated in cohorts from 65 mg/m² to 80 mg/m², 90 mg/m², and 100 mg/m² in combination with a fixed dose of carboplatin. Carboplatin was dosed using the Calvert's formula based on the targeted area under the time-concentration curve (AUC) of 6 mg/mL · min. The cycles were repeated every 3 weeks. Dose-limiting toxicity was defined as: nonreversible grade 3 or greater nonhematologic toxicity; grade 4 emesis despite the use of antiemetics; grade 4 neutropenia lasting more than 7 days; or febrile neutropenia.

Febrile neutropenia was dose limiting. Other rare salient toxicities observed were hypotension, low back pain, nausea, and fatigue. The recommended phase II doses of docetaxel for further evaluation were 90 mg/m² and 80 mg/m² with and without G-CSF support, in combination with a fixed dose of carboplatin (AUC = 6 mg/mL · min).

Based on the results of this phase I study,[22] a phase II study of the combination of docetaxel and carboplatin has been initiated for patients with stage IIIB and IV non-small-cell lung cancer (Table 3). In this study, the duration of dexamethasone (8 mg twice daily) administration has been reduced to 3 days from 5 days. The results of this study will provide further insight into the effectiveness of this combination against non-small-cell lung cancer.

Future Directions With Docetaxel and Platinum Compounds

The combinations of docetaxel with either carboplatin or cisplatin are being evaluated further in large randomized trials for patients with metastatic and advanced non-small-cell lung cancer. These regimens are also being investigated in patients with earlier stages of non-small-cell lung cancer in the neoadjuvant setting. Supportive care agents such as amifostine and thrombopoietin are being added to further refine these regimens and attempt to decrease the overall toxicity.

Future studies will also incorporate new agents with activity in non- small-cell lung cancer, such as vinorelbine (Navelbine) and gemcitabine (Gemzar), with these regimens to develop three-drug combinations for evaluation in non-small-cell lung cancer.

References

1. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991.

2. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991.

3. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70:384-387, 1994.

4. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232-1237, 1994.

5. Burris HA, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small cell lung cancer (abstract 1116). Proc Am Soc Clin Oncol 12:335, 1993.

6. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238-1244, 1994.

7. Watanabe K: Personal communication.

8. Miller VA, Rigas JR, Francis PA, et al: Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small lung cancer. Cancer 75:968-972, 1995.

9. Lira-Puerto V, Zepeda G, Mohar A, et al: Phase-II trial of Taxotere (docetaxel) in advanced non-small cell lung cancer (abstract 1186). Proc Am Soc Clin Oncol 14:382, 1995.

10. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13:645-651, 1995.

11. Gandara DR, Vokes E, Green M, et al: Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival in a multicenter trial (abstract 1632). Proc Am Soc Clin Oncol 16, 1997.

12. Marino P, Pampalloona S, Preatoni P, et al: Chemotherapy vs supportive care in non-small-cell lung cancer: Results of a meta-analysis of the literature. Chest 106:861-865, 1994.

13. Millward MJ, Zalcberg J, Bishop JF, et al: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 15:750-758, 1997.

14. Pronk LC, Schellens JH, Planting AS, et al: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15:1071-1091, 1997.

15. Belani CP, Bonomi P, Dobbs T, et al: Multicenter phase II trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer (abstract 1660). Proc Am Soc Clin Oncol 16:221a, 1997.

16. Zalcberg JR, Bishop JF, Millward MJ, et al: Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) (abstract 1084). Eur J Cancer 31A(suppl 5):S226, 1995.

17. Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC): An interim analysis (abstract 1059). Proc Am Soc Clin Oncol 14:350, 1995.

18. Androulakis N, Dimopoulos AM, Kourousis C, et al: First-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel and cisplatin: A multicenter phase II study (abstract 1655). Proc Am Soc Clin Oncol 16, 1997.

19. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989.

20. Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1, 1 cyclobutane-decarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982.

21. Curt GA, Grygeil JJ, Corden BJ, et al: A phase I and pharmacokinetic study of diammine-cyclobutane-decarboxylate-platinum (NSC 241240). Cancer Res 43:4470-4473, 1983.

22. Belani CP, Hadeed V, Ramanathan R, et al: Docetaxel and carboplatin: A phase I and pharmacokinetic trial for advanced non-hematologic malignancies (abstract 771). Proc Am Soc Clin Oncol 16, 1997.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.